ALVOTECH S.A.S
ALVOTECH S.A.S
Action · LU2458332611 · ALVO · A3DK8U (XNMS)
Aperçu Indicateurs financiers
9,13 EUR
-0,57 % -0,05 EUR
Frankfurt (XNAS) · Cours et graphiques actuels sur MoneyPeak
10.06.2025 18:30

Cours actuels de ALVOTECH S.A.S

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
ALVO
USD
10.06.2025 18:30
10,44 USD
10,65 USD
-1,97 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
-0,77 % -8,83 % 6,16 % -11,43 % -14,71 % -29,95 % -7,14 %

Firmenprofil zu ALVOTECH S.A.S Aktie

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Unternehmensdaten

Name ALVOTECH S.A.S
Firma Alvotech
Symbol ALVO
Website https://www.alvotech.com
Heimatbörse XNMS Frankfurt
WKN A3DK8U
ISIN LU2458332611
Wertpapierart Aktie
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
CEO Mr. Robert Wessman
Marktkapitalisierung 3 Mrd.
Land Island
Währung EUR
Mitarbeiter 1,0 T
Adresse Saemundargata 15-19, 102 Reykjavik
IPO Datum 2022-06-16

Ticker Symbole

Name Symbol
Frankfurt Z45.F
NASDAQ ALVO

Weitere Aktien

Investoren die ALVOTECH S.A.S die halten, haben auch folgende Aktien im Depot:
IDB TRUST SERVICES LIMITED TST CERT 12/04/22
IDB TRUST SERVICES LIMITED TST CERT 12/04/22 Anleihe
SK Growth Opportunities Corporation - Warrant
SK Growth Opportunities Corporation - Warrant Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025